Effects of continuous subcutaneous insulin infusion on renal morphology in experimental diabetes. I. Blood glucose levels, body size, kidney weight and glomerulo-tubular morphometry

1987 ◽  
Vol 151 (2) ◽  
pp. 147-155 ◽  
Author(s):  
Terry M. Mayhew ◽  
Ashutosh K. Sharma ◽  
Kenneth N. C. McCallum
Keyword(s):  
Body Size ◽  
Blood Glucose ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Experimental Diabetes ◽  
Subcutaneous Insulin ◽  
Kidney Weight ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Renal Morphology

Clinical Usefulness of a Bolus Calculator in Maintaining Normoglycaemia in Active Professional Patients with Type 1 Diabetes Treated with Continuous Subcutaneous Insulin Infusion

2008 ◽  
Vol 36 (5) ◽  
pp. 1112-1116 ◽  
Author(s):  
T Klupa ◽  
T Benbenek-Klupa ◽  
M Malecki ◽  
M Szalecki ◽  
J Sieradzki
Keyword(s):  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Metabolic Control ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Target Range ◽  
Subcutaneous Insulin ◽  
Glucose Levels ◽  
Blood Glucose Levels

This observational study assessed metabolic control in young, active professionals with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) with or without the use of a bolus calculator. Eighteen patients aged 19 − 51 years with diabetes duration of 6 − 22 years were included; eight patients used a bolus calculator and 10 did not. Metabolic control was assessed by glycosylated haemoglobin (HbA1c) measurements and blood glucose profiles. A continuous glucose monitoring system (CGMS) was also used by three patients from each group. Mean HbA1c and fasting blood glucose levels were not significantly different between the two groups, but mean post-prandial blood glucose was significantly lower in bolus calculator users than non-users. The CGMS showed more blood glucose levels within the target range in bolus calculator users than non-users, but statistical significance was not achieved. In conclusion, a bolus calculator may help to improve post-prandial blood glucose levels in active professional type 1 diabetes patients treated with CSII, but does not have a major impact on HbA1c levels.

scholarly journals Pump insulin therapy for diabetes mellitus

2009 ◽  
Vol 55 (2) ◽  
pp. 10-14
Author(s):  
A O Emel'yanov
Keyword(s):  
Blood Glucose ◽  
Insulin Therapy ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Pharmaceutical Treatment ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Patients With Diabetes ◽  
Key Features ◽  
Normalize Blood Glucose Level

Insulin therapy is a pharmaceutical treatment used for patients with diabetes to normalize blood glucose level. In patients receiving insulin therapy, optimization of blood glucose levels can be achieved using various types of insulin and various methods, such as MDI (multiple daily injections) and CSII (continuous subcutaneous insulin infusion). This review describes actual key features of CSII for diabetes patients.

Comparative analysis of different drug delivery methods of injectable hydrogel nanomaterials of insulin biomaterials via multiple daily injections and continuous subcutaneous insulin infusion in the treatment of type 1 diabetes mellitus in children

2021 ◽  
Vol 11 (7) ◽  
pp. 1154-1160
Author(s):  
Yan Sun ◽  
Haoshu Niu ◽  
Zhixia Wang ◽  
Ying Wang ◽  
Xuechun Li ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Drug Delivery ◽  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Type 1 Diabetes Mellitus ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Insulin Dosage ◽  
Subcutaneous Insulin

The aim of this study was to investigate the difference between multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) in blood glucose control during the treatment of type 1 diabetes mellitus (T1DM) in children. under the nano-hydrogel delivery carrier. In order to improve the efficiency and therapeutic effect of the experiment, this paper adopts injectable nanomaterial-polymer composite hydrogel as drug delivery system to cooperate with insulin injection to improve the effective utilization of drugs. Eighty children diagnosed with T1DM by the department of Endocrinology, Genetics, and Metabolism of INNER MONGOLIA BAOGANG Hospital from October 2018 to December 2019 were selected as research subjects for this study. The children were randomly divided into MDI group (treated with MDI) and CSII group (treated with CSII), with 40 children in each group. The basic data of the children were compared, and changes in hemoglobin A1c (HbA1c) at admission and 1, 2, and 3 months after treatment were detected. During the detection, the blood glucose level, therapeutic time of blood glucose normalization, and daily insulin dosage were recorded. The HbA1c and fasting blood glucose (FBG) were followed up three months after discharge, and incidences of hypoglycemia in the two groups were observed. The results showed that the mean value of HbA1c in the MDI group was higher than that in the CSII group (P < 0.05). Each patient was assessed for the number of times their blood sugar was allowed to dip below normal levels; patients with less hypoglycemia had a higher rate of blood sugar control. The control rates of blood glucose in the MDI and CSII groups were 19.21% and 23.50%, respectively. The CSII group showed significantly higher blood glucose rates than the MDI group (P < 0.05). The therapeutic time of blood glucose normalization in the MDI group was significantly longer than that in the CSII group (P < 0.05). There was no significant difference in the average daily insulin dosage between the MDI and CSII groups (P > 0.05), which indicated that CSII therapy had significant advantages in reducing blood glucose in children with T1DM.

scholarly journals Understanding safety differently: developing a model of resilience in the use of intravenous insulin infusions in hospital in-patients—a feasibility study protocol

BMJ Open ◽  
2019 ◽  
Vol 9 (7) ◽  
pp. e029997
Author(s):  
Mais Hasan Iflaifel ◽  
Rosemary Lim ◽  
Kath Ryan ◽  
Clare Crowley ◽  
Rick Iedema
Keyword(s):  
Blood Glucose ◽  
Phase I ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Insulin Infusion ◽  
University Hospitals ◽  
Glucose Levels ◽  
Oxford University ◽  
Intravenous Insulin ◽  
Blood Glucose Levels

BackgroundIntravenous insulin infusions are considered the treatment of choice for critically ill patients and non-critically ill patients with persistent raised blood glucose who are unable to eat, to achieve optimal blood glucose levels. The benefits of using intravenous insulin infusions as well as the problems experienced are well described in the scientific literature. Traditional approaches for improving patient safety have focused on identifying errors, understanding their causes and designing solutions to prevent them. Such approaches do not take into account the complex nature of healthcare systems, which cannot be controlled solely by following standards. An emerging approach called Resilient Healthcare proposes that, to improve safety, it is necessary to focus on how work can be performed successfully as well as how work has failed.Methods and analysisThe study will be conducted at Oxford University Hospitals NHS Foundation Trust and will involve three phases. Phase I: explore how work is imagined by analysing intravenous insulin infusion guidelines and conducting focus group discussions with guidelines developers, managers and healthcare practitioners. Phase II: explore the interplay between how work is imagined and how work is performed using mixed methods. Quantitative data will include blood glucose levels, insulin infusion rates, number of hypoglycaemic and hyperglycaemic events from patients’ electronic records. Qualitative data will include video reflexive ethnography: video recording healthcare practitioners using intravenous insulin infusions and then conducting reflexive meetings with them to discuss selected video footage. Phase III: compare findings from phase I and phase II to develop a model for using intravenous insulin infusions.Ethics and disseminationEthical approvals have been granted by the South Central—Oxford C Research Ethics Committee, Oxford University Hospitals NHS Foundation Trust and University of Reading. The results will be disseminated through presentations at appropriate conferences and meetings, and publications in peer-reviewed journals.

Sign in / Sign up

Export Citation Format

Share Document